Table 4.

Building Mediation Analysis

	ß	Exp (ß)	Lower 95% CI	Upper 95% CI	Pr (>|z|)
Estimating direct effect on all‐cause at 1‐y follow up
(Intercept)	−2.9846	0.05	0.03	0.07	<0.001
CKD 4–5—eGFR <30 (mL/min per 1.73 m2)	1.2841	3.61	2.42	5.40	<0.001
Bleedings (BARC 2, 3, or 5)	0.7427	2.10	1.51	2.93	<0.001
Contrast dose Q1 <137 mL [reference category]
Q2 137–180 mL	−0.0271	0.97	0.59	1.59	0.9141
Q3 181–250 mL	0.2585	1.29	0.81	2.08	0.2851
Q4 >250 mL	0.7041	2.02	1.29	3.18	0.0023
Estimating effect on mediator (AKI)
(Intercept)	−2.622	0.07	0.05	0.10	<0.001
CKD 4–5—eGFR <30 (mL/min per 1.73 m2)	1.537	4.65	3.32	6.52	<0.001
Bleedings (BARC 2, 3, or 5)	0.441	1.55	1.19	2.03	0.0013
Contrast dose Q1 <137 mL [reference category]
Q2 137–180 mL	0.578	1.78	1.20	2.65	0.0042
Q3 181–250 mL	0.918	2.50	1.70	3.68	<0.001
Q4 >250 mL	1.144	3.14	2.13	4.62	<0.001
Estimating overall effect on all‐cause at 1‐y follow up
(Intercept)	−3.0324	0.05	0.03	0.07	<0.001
CKD 4–5—eGFR <30 (mL/min per 1.73 m2)	1.1176	3.06	2.01	4.64	<0.001
AKI	0.6065	1.83	1.27	2.65	0.0012
Bleedings (BARC 2, 3, or 5)	0.7013	2.02	1.44	2.81	<0.001
Contrast dose Q1 <137 mL [reference category]
Q2 137–180 mL	−0.0663	0.94	0.57	1.54	0.7931
Q3 181–250 mL	0.1907	1.21	0.75	1.95	0.4338
Q4 >250 mL	0.6099	1.84	1.16	2.91	0.0092

AKI indicates acute kidney injury; BARC, Bleeding Academic Research Consortium ²⁰ ; CKD, chronic kidney disease; eGFR, estimated glomerular filtration rate; and Q, quartile.